Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025

Thank you for your support and sharing:

Good news every one! We are almost there. Essentialis Announces the Dosing of the First Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025.
Patients who completed the first two phases of clinical study PC025 are currently being enrolled in a 6-month open label extension.  The objective of the extension is to document the long-term therapeutic benefits of DCCR, Essentialis’ lead drug, on hyperphagia, body fat, lean body mass, aggressive, threatening and destructive behaviors and on stamina. Read More